Poolbeg Pharma
POLB · AIM · Health Care · mcap £46m · 6.4p
Poolbeg develops medicines for cancer immunotherapy-induced cytokine release syndrome (POLB 001) and an oral GLP-1 delivery technology for obesity. It aims to partner or commercialise these assets and holds patents and FDA Orphan Drug Designation for POLB 001.
Timeline · every situation
dots = announcementsClosed · 1
Company filings. Not investment advice.